ArticleNeuro-oncology advances

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.

Samuel A Goldlust et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.